These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37521350)

  • 1. Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed.
    Ceci A; Conte R; Didio A; Landi A; Ruggieri L; Giannuzzi V; Bonifazi F
    Front Med (Lausanne); 2023; 10():1113460. PubMed ID: 37521350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
    Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
    Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
    [No Abstract]   [Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016.
    Lasala R; Santoleri F; Zanon D; Romagnoli A; Abrate P; Costantini A; Musicco F
    J Oncol Pharm Pract; 2023 Jan; 29(1):83-87. PubMed ID: 34693799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mandatory requirements for pediatric drug development in the EU and the US for novel drugs-A comparative study.
    Christiansen H; De Bruin ML; Hallgreen CE
    Front Med (Lausanne); 2022; 9():1009432. PubMed ID: 36388912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the European pediatric medicine regulation working for children and adolescents with cancer?
    Vassal G; Geoerger B; Morland B
    Clin Cancer Res; 2013 Mar; 19(6):1315-25. PubMed ID: 23329813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
    Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of legislation on drug substances used off-label in paediatric wards--a nationwide study.
    Haslund-Krog S; Mathiasen R; Christensen HR; Holst H
    Eur J Clin Pharmacol; 2014 Apr; 70(4):445-52. PubMed ID: 24398969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.